deltatrials
Terminated PHASE2 INTERVENTIONAL 5-arm NCT04167345

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects

Sponsor: Vertex Pharmaceuticals Incorporated

Conditions Alpha 1-Antitrypsin Deficiency
Interventions Placebo VX-814
Updated 16 times since 2019 Last updated: Jan 7, 2022 Started: Jan 13, 2020 Primary completion: Nov 14, 2020 Completion: Nov 14, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

at Sponsor's discretion

Other terminated trials from Vertex Pharmaceuticals Incorporated

See all terminations from Vertex Pharmaceuticals Incorporated

Other Alpha 1-Antitrypsin Deficiency trials with similar outcome

Browse all Alpha 1-Antitrypsin Deficiency trials

This PHASE2 trial investigates Alpha 1-Antitrypsin Deficiency and is currently terminated or withdrawn. Vertex Pharmaceuticals Incorporated leads this study, which shows 16 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2019 – ~Feb 2020 · 2 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Jul 2020 · 30 days · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2022 · 14 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Mar 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Mar 2022 [monthly]

    Terminated PHASE2

▶ Show 11 earlier versions

  1. Dec 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  2. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  3. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE2

  4. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  5. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  6. Jun 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  7. May 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Dec 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vertex Pharmaceuticals Incorporated
Data source: Vertex Pharmaceuticals Incorporated

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Beaumont, Ireland , Birmingham, United States , Chapel Hill, United States , Charleston, United States , Cincinnati, United States , Cleveland, United States , Denver, United States , Essen, Germany , Falls Church, United States and 18 more locations